Design Therapeutics, Inc.
DSGN
$5.41
$0.214.04%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | 41.10M | 41.00M | 35.42M | 34.28M | 35.66M |
Gross Profit | -41.10M | -41.00M | -35.42M | -34.28M | -35.66M |
SG&A Expenses | 19.78M | 18.48M | 18.03M | 17.61M | 18.80M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 74.93M | 68.40M | 62.38M | 60.81M | 63.39M |
Operating Income | -74.93M | -68.40M | -62.38M | -60.81M | -63.39M |
Income Before Tax | -63.49M | -56.20M | -49.59M | -47.78M | -50.53M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -63.49 | -56.20 | -49.59 | -47.78 | -50.53 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -63.49M | -56.20M | -49.59M | -47.78M | -50.53M |
EBIT | -74.93M | -68.40M | -62.38M | -60.81M | -63.39M |
EBITDA | -74.31M | -67.79M | -61.79M | -60.23M | -62.82M |
EPS Basic | -1.12 | -0.99 | -0.88 | -0.85 | -0.90 |
Normalized Basic EPS | -0.70 | -0.62 | -0.55 | -0.53 | -0.56 |
EPS Diluted | -1.12 | -0.99 | -0.88 | -0.85 | -0.90 |
Normalized Diluted EPS | -0.70 | -0.62 | -0.55 | -0.53 | -0.56 |
Average Basic Shares Outstanding | 226.92M | 226.62M | 226.35M | 225.76M | 225.12M |
Average Diluted Shares Outstanding | 226.92M | 226.62M | 226.35M | 225.76M | 225.12M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |